КАРДИОРЕНАЛЬНЫЙ СИНДРОМ: ОПРЕДЕЛЕНИЕ, КЛАССИФИКАЦИЯ И КЛИНИЧЕСКИЕ ОСОБЕННОСТИ
Аннотация
Кардиоренальный синдром: определение, классификация и клинические особенности
Библиографические ссылки
1. Ronco С. Cardiorenal and renocardiac syndromes: clinical disorders in search of a systematic definition. Int. J. Artif. Organs. 2008;31:1-2
2. Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit. Care Med. 2008;36:S75-S88.
3. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong Intensive. Care Med. 2008;34:957-962.
4. Patel J, Heywood JT. Management of the cardiorenal syndrome in heart failure. Curr. Cardiol. Rep. 2006;8:211-216.
5. Silverberg DS, Wexler D, Iaina A. et al. Anemia, chronic renal disease and congestive heart failure— the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int. Urol. Nephrol. 2006;38:295-310.
6. Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: ‘guyton revisited.’ Eur. Heart J. 2005;26:11-17.
7. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin. J. Am. Soc. Nephrol. 2006;1:8-18.
8. M ebazaa A, Gheorghiade M, Pina IL, et al. Practical recommendations for prehospital and early in-hospital management o f patients presenting with acute heart failure syndromes. Crit. Care Med. 2008;36:S 129-SI 39.
9. Adams JrKF, FonarowGC,Em erm an CL, et al. Characteristics and outcomes o f patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am. Heart J. 2005;149:209-216.
10. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes o f patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J. Am. Coll. Cardiol. 2007;50:768-777.
11. Jose P, Skali H, Anavekar N, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J. Am. Soc. Nephrol. 2006; 17:2886- 2891.
12. Goldberg A, Hammerman H, Petcherski S, et al. Inhospital and I-year mortality of patients who develop worsening renal function following acute ST-clevation myocardial infarction. Am. Heart J. 2005; 150:330-337.
13. Tokuyama H, Kelly DJ, Zhang Y, et al. Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia. Nephron Physiol. 2007; 106:54-62.
14. Ellison DH. Diuretic resistance: physiology and therapeutics. Semin. Nephrol. 1999;19:581-597.
15. Almeshari K, Ahlstrom NG, Capraro FE, Wilcox CS. A volume-independent component to postdiuretic sodium retention in humans. J. Am. Soc. Nephrol. 1993;3:1878-1883.
16. Verma A, Solomon SD. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist. Curr. Heart Fail. Rep. 2007;4:183-189.
17. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-1632.
18. Yorgun H, Deniz A, Aytemir K. Cardiogenic shock secondary to combination of diltiazem and sotalol. Intern Med. J. 2008;38:22l-222.
19. Tessone A, Gottlieb S, Barbash IM, et al. Underuse o f standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency. Cardiology 2007;108:193-199.
20. Roghi A, Savonitto S, Cavallini C, et al. Impact o f acute renal failure following percutaneous coronary intervention on long-term. J. Cardiovasc. Med. 2008;9:375-381.
21. Witteles RM, Kao D, Christopherson D, et al. Impact o f nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol. 2007;50:1835-1840.
22. McCullough PA. Contrast induced nephropathy. J. Am. Coll. Cardiol. 2008;51:1419- 1428.
23. Han WK, Bonventre JV. Biologic markers for the early detection o f acute kidney injuiy. Curr. Opin. Crit. Care 2004;10:476-482.
24. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J. Am. Coll. Card. 2008;52:1527-1539.
25. Haase M, Devarajan P. Haase-Fielitz A. et al. The Outcome o f Neutrophil Gelatinase- Associated Lipocalin-Positive Subclinical Acute Kidney Injury: A Multicenter Pooled Analysis of Prospective Studies. J. Am.Coll. Cardiol.2011; 57(17): 1752 - 1761.
26. Wagener G, Jan M, Kim M, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006; 105:485-491.
27. Parikh CR, Jani A, Mishra J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant 2006;6:I639- 1645.
28. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am. J. Nephrol. 2006;26:287-292.
29. Zappitelli M, Washburn KK, Arikan АА, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker o f acute kidney injury in critically ill children: a prospective cohort study. Crit. Care 2007; 11:R84.
30. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin С is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am. J. Kidney Dis. 2002;40:221-226.
31. Herget-Rosenthal S, M arggraf G, Husing J, et al. Early detection o f acute renal failure by serum cystatin C. Kidney Int. 2004;66:1115- 1122.
32. VandeVoorde RG, Katlman TI, Ma Q, et al. Serum NGAL and cystatin С as predictive biomarkers for acute kidney injury. J. Am. Soc. Nephrol. 2006; 17:404A.
33. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection o f kidney tubular injury. Am. J. Physiol. Renal Physiol. 2006;290:F517-F529.
34. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor o f outcome in a broad spectrum o f patients with heart failure. Circulation 2006;113:671-678.
35. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 2006;355:260-269.
36. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions— insights form the ESCAPE trial. J. Am. Coll. Cardiol. 2007;51:1268- 1274.
37. Jie KE, Verhaar MC, Cramer MJ, et al. Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am. J. Physiol. Renal. Physiol. 2006;291 :F932-F944.
38. Fu P, Arcasoy MO. Erythropoietin protects cardiac myocytes against anthracycline- induced apoptosis Biochem. Biophys. Res. Commun. 2007;354:372-378.
39. Palazzuoli A, Silverberg DS, Iovine F, et al. Effects o f beta-erythropoietin treatment on left ventricular remodeling, systolic function, and В-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am. Heart J. 2007; 154:645e9—15.
40. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development o f worsening renal function among hospitalized patients. Am. Heart J. 2004; 147:331-338.
41. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-1009.
42. Hjalmarson A, Goldstein S, Fagerberg B, et al. MERIT-HF Study Group Effects o f controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000;283:1295-1302.
43. Uchino S, Bellomo R, Goldsmith D, et al. An assessment o f the RIFLE criteria for acute renal failure in hospitalized patients. Crit. Care Med. 2006;34:1913-1917.
44. Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation o f the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol. Dial. Transplant. 2008;23:1203- 1210.
45. Blake P, Hasegawa Y, Khosla MC, et al. Isolation o f ’’myocardial depressant factor(s)” from the ultrafiltrate o f heart failure patients with acute renal failure. ASAIO J. 1996;42:M911-M915.
46. M eyer TW, Hostetter TH. Uremia N. Engl. J. Med. 2007;357:1316-1325.
47. Figueras J, Stein L, Diez V, et al. Relationship between pulmonary hemodynamics and arterial pH and carbon dioxide tension in critically ill patients. Chest 1976;70:466-472.
48. Brady JP, Hasbargen JA. A review of the effects o f correction o f acidosis on nutrition in dialysis patients. Semin. Dial. 2000;13:252-255.
49. M cCullough PA, Sandberg KR. Chronic kidney disease and sudden death: strategies or prevention. Blood Purif. 2004;22:136-142.
50. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for the management o f patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society o f Interventional Radiology, Society for Vascular M edicine and Biology, and the American College o f Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management o f Patients With Peripheral Arterial Disease). J. Am. Coll. Cardiol. 2006;47:eI-eI92.
51. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur. J. Clin. Invest. 2007;37:350-356.
52. Maisel A, Hollander JE, GussD, et al. Primary results o f the rapid emergency department heart failure outpatient trial (REDHOT). A multicenter study o f В-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J. Am. Coll. Cardiol. 2004;44:1328-1333.
53. Austin WJ, Bhalla V, Hernandez- Arce I, et al. Correlation and prognostic utility of В-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am. J. Clin. Pathol. 2006;126:506-512.
54. Liang F, O ’Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating В-type natriuretic peptide. J. Am. Coll. Cardiol. 2007;49:1071-1078.
55. Spanaus KS, Kronenberg F, Ritz E, et al. В-type natriuretic peptide concentrations predict the progression o f nondiabetic chronic kidney disease: the mild-to-moderate kidney disease study. Clin. Chem. 2007;53:1264-1272.
56. Loria V, Dato I, Graziani F, Biasucci LM. M yeloperoxidase: a new biomarker o f inflammation in ischemic heart disease and acute coronary syndromes.Mediators Inflamm. 2008;2008:135625.
57. Braunwald E. Biomarkers in heart failure. N. Engl. J. Med. 2008;358:2148-2159.
58. Chen D, Assad-Kottner C, Orrego C, Torre-Amione G. Cytokines and acute heart failure. Crit. Care Med. 2008;36:S9-S16.
59. Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J. Am. Soc. Nephrol. 2003;14:1549-1558.
60. Ronco C, Bellomo R, Ricci Z. Continuous renal replacement therapy in critically ill patients. Nephrol. Dial. Transplant. 2001 ;16(Suppl 5):67-72.
61. National Kidney Foundation К/ DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002;39:S1-S266.
62. Coresh J, Astor BC, Greene T, et al. Prevalence o f chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003;41:1-12.
63. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology o f cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998;32:SI 12-SI 19.
64. Herzog CA. Dismal long-term survival o f dialysis patients after acute myocardial infarction: can we alter the outcome? Nephrol. Dial. Transplant. 2002; 17:7-10.
65. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int. Suppl. 2003;87:S24-S31.
66. Johnson DW, Craven AM, Isbel NM. Modification o f cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int. 2007;11:1-14.
67. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications o f abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002;106:974-980.
68. Gibson CM, Pinto DS, Murphy SA, et al. Association o f creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J. Am. Coll. Cardiol. 2003;42:1535-1543.
69. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 2001 ;38:955-962.
70. Sorensen CR, Brendorp B, Rask- Madsen C, Kober L, Kjoller E, Torp-Pedersen C. The prognostic importance o f creatinine clearance after acute myocardial infarction. Eur. Heart J. 2002;23:948-952.
71. Tokmakova MP, Skali H, KenchaiahS, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study. Circulation 2004; 110:3667-3673.
72. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 2004;351:1285-1295.
73. cCullough PA. Cardiorenal risk: an important clinical intersection. Rev. Cardiovasc. Med. 2002;3:71-76.
74. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann. Intern. Med. 2002;137:563-570.
75. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J. Am. Coll. Cardiol. 2003;42:201-208.
76. Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur. J. Clin. Invest. 2006;36(Suppl 3):78-88.
77. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an Al adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105:1348-1353.
78. Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects o f tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004;291:1963-1971.
79. Duffield JS, Hong S, Vaidya VS, et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 2006;177:5902-5911.
80. Sakata Y, Masuyama T, Yamamoto K, et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention o f heart failure in hypertensive rats. Circulation 2000;102:2269-2275.
81. Keltai M, Tonelli M, Mann JF, et al. Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel. Eur. J. Cardiovasc. Prev. Rehabil. 2007;14:312-318.
82. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111:14 8 7 -1491.
83. Ruggenenti P, Perna A, RemuzziG, Gruppo Italiano di Studi Epidemiologici in Nefrologia ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis o f the REIN trial results. Ramipril Efficacy In Nephropathy. J. Am. Soc. Nephrol. 2001;12:2832-2837.
84. Bakris GL, Weir MR. Angiotensin- converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med. 2000;160:685-693.
85. Han SW, Won YW, Yi JH, Kim HJ. No impact o f hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol. Dial. Transplant. 2007;22:1150- 1155.
86. Roy P, Bouchard J, Amyot R, Madore F. Prescription patterns o f pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am. J. Kidney Dis. 2006;48:645-651.
87. Jessup M. Aldosterone blockade and heart failure. N. Engl. J. Med. 2003;348:1380-1382.
88. Juurlink DN, Mamdani MM, Lee DS, et al. Rates o f hyperkalemia after publication of the randomized aldactone evaluation study. N. Engl. J. Med. 2004;351:543-551.
89. Cunningham PN, Dyanov HM, Park P, et al. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J. Immunol. 2002;168:5817-5823.
90. Kumar A, Paladugu B, Mensing J, et al. Nitric oxide-dependent and -independent mechanisms are involved in TNF-alpha-induced depression o f cardiac myocyte contractility. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;292:R 1900-R1906.
91. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit. Care Med. 2000;28:3581-3587.
92. Bellomo R, Ronco C, Kellum JA, et al. Acute Dialysis Quality Initiative Workgroup Acute renal failure— definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit. Care 2004;8:R204-R212.
93. Bagshaw SM, Delaney A, Haase M, et al. Loop diuretics in the management o f acute renal failure: a systematic review and meta-analysis. Crit. Care Resusc. 2007;9:60-68.
94. Duke GJ. Renal protective agents: a review. Crit. Care Resusc. 1999; 1:265-275.
95. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N. Engl. J. Med. 2008;358:125-139.
96. Voors AA, Dittrich HC, Massie BM, P. et al.Effects o f the Adenosine Al Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction: Results From PROTECT (Placebo-Controlled Randomized Study o f the Selective AI Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J. Am. Coll. Cardiol. 2011 ;57(19): 899 - 1907.
